

Paul A Bunn Jr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7428991/publications.pdf>

Version: 2024-02-01

64
papers

8,643
citations

136885

32
h-index

143943

57
g-index

64
all docs

64
docs citations

64
times ranked

10252
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 1998.	3.8	1,386
2	Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Nonâ€“Small-Cell Lung Cancer: A Southwest Oncology Group Trial. Journal of Clinical Oncology, 2001, 19, 3210-3218.	0.8	1,072
3	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1807-1814.	0.5	585
4	Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6838-6845.	0.8	574
5	Small-cell lung cancer: what we know, what we need to know and the path forward. Nature Reviews Cancer, 2017, 17, 725-737.	12.8	558
6	New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet, The, 2016, 388, 1012-1024.	6.3	381
7	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2015, 10, 768-777.	0.5	357
8	NCI-navy medical oncology branch cell line data base. Journal of Cellular Biochemistry, 1996, 63, 32-91.	1.2	244
9	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 3824-3830.	0.8	244
10	Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology, 2016, 11, 613-638.	0.5	231
11	Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Nonâ€“Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial. Journal of Clinical Oncology, 2010, 28, 1843-1849.	0.8	206
12	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
13	Recent Clinical Advances in Lung Cancer Management. Journal of Clinical Oncology, 2014, 32, 973-982.	0.8	203
14	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 3334-3347.	3.2	182
15	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963.	0.5	173
16	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	0.5	156
17	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutationsâ€“The Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research, 2018, 24, 1038-1047.	3.2	154
18	Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. Oncologist, 2015, 20, 316-322.	1.9	151

#	ARTICLE	IF	CITATIONS
19	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. <i>Journal of Thoracic Oncology</i> , 2019, 14, 876-889.	0.5	141
20	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133
21	<i>HER2</i> mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2017, 123, 4099-4105.	2.0	132
22	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1717-1726.	0.5	119
23	MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1666-1671.	0.5	115
24	Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 691-700.	0.5	108
25	Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers. <i>Cancer Prevention Research</i> , 2011, 4, 793-802.	0.7	104
26	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <i>BRAF</i> mutations in the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2015, 121, 448-456.	2.0	102
27	Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2314-2322.	1.9	81
28	Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. <i>Journal of Clinical Oncology</i> , 2002, 20, 23S-33S.	0.8	75
29	Epidermal growth factor receptor immunohistochemistry. <i>Cancer</i> , 2008, 112, 1114-1121.	2.0	69
30	Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1478-1481.	1.2	58
31	T-Cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: History and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). <i>Journal of Cellular Biochemistry</i> , 1996, 63, 12-23.	1.2	56
32	Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 87-94.	0.8	51
33	High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. <i>Lung Cancer</i> , 2005, 49, 187-191.	0.9	29
34	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e191-e204.	1.1	26
35	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. <i>Journal of Thoracic Oncology</i> , 2022, 17, 214-227.	0.5	26
36	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 134-138.	0.5	21

#	ARTICLE	IF	CITATIONS
37	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. <i>Lung Cancer</i> , 2016, 96, 27-32.	0.9	20
38	2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472.	1.9	17
39	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339.	1.1	15
40	A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. <i>Lancet Oncology</i> , The, 2012, 13, 442-443.	5.1	11
41	Growth factors in lung cancer: Possible etiologic role and clinical target. <i>Medical and Pediatric Oncology</i> , 1991, 19, 449-458.	1.0	8
42	The Evolution of Tumor Classification: A Role for Genomics?. <i>Cancer Cell</i> , 2013, 24, 693-694.	7.7	8
43	Broad-Based Molecular Testing for Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 445.	3.8	7
44	Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1727-1737.	0.5	7
45	New Developments in Neoadjuvant Therapy for Lung Cancer. <i>Oncology</i> , 2019, 33, 101-6, 109.	0.4	6
46	Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 689-690.	12.5	5
47	Chemotherapeutic options in lung cancer. <i>Cancer</i> , 1998, 83, 1740-1750.	2.0	4
48	Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?. <i>Clinical Cancer Research</i> , 2014, 20, 1727-1729.	3.2	4
49	Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. <i>Clinical Lung Cancer</i> , 2015, 16, 245-251.	1.1	4
50	Personalized one-two punches for lung cancer. <i>Cell Research</i> , 2015, 25, 269-270.	5.7	4
51	International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2022, , .	0.5	4
52	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 510.	1.3	3
53	Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. <i>Lung Cancer</i> , 2018, 118, 148-154.	0.9	2
54	Advances in lung cancer. <i>Oncotarget</i> , 2017, 8, 78247-78248.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Early-stage NSCLC: the role of radiotherapy and systemic therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2 Suppl 2, S31-40.	2.3	2
56	Reply to A. Brailon. Journal of Clinical Oncology, 2014, 32, 3575-3575.	0.8	1
57	Progress in research on screening and genetics in lung cancer. Lancet Respiratory Medicine, 2014, 2, 19-21.	5.2	1
58	Lessons Learned From the Systematic Evaluation of Cutaneous T-Cell Lymphomas at the National Cancer Institute and the Roadmap for Future Studies. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S74-S79.	0.2	0
59	Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. Cancer, 2016, 122, 674-675.	2.0	0
60	Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectrum, 2021, 5, pkab014.	1.4	0
61	Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. JTO Clinical and Research Reports, 2022, 3, 100269.	0.6	0
62	Seminars in oncology. Introduction. Seminars in Oncology, 2002, 29, 1-2.	0.8	0
63	How gradual retirement has allowed me to spend more time with family and being physically active. Clinical Advances in Hematology and Oncology, 2020, 18, 17-18.	0.3	0
64	Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?. Clinical Cancer Research, 2022, , OF1-OF2.	3.2	0